ALT
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Altimmune, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALT alertsX4 Pharmaceuticals, Inc reported in an 8-K filed September 17, 2025 that Christophe Arbet-Engels resigned as Chief Medical Officer, effective September 16, 2025. The proxy statement of X4 Pharmaceuticals, Inc reports total compensation of $1,636,930 for Christophe Arbet-Engels in fiscal 2023, including a base salary of $179,590. Christophe Arbet-Engels has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Altimmune, Inc. on November 12, 2026. Altimmune, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Altimmune, Inc. includes Jerome Durso (CEO and Board Member), Vipin K. Garg (CEO), William Enright (CEO) and 7 others.
“On September 16, 2025, Dr. Christophe Arbet-Engels informed the Company of his resignation as the Company's Chief Medical Officer, effective as of September 16, 2025.”
“I'd like to start by just stating that I am very pleased with the significant progress we are making as we advance our clinical programs across MASH, AUD, and ALD.”
“So first, we know that GLP takes a long time to have the effect because it's an indirect effect. So the direct effect of glucagon on the liver is important in these patients early on so that they can see the benefits of this.”
“I am very excited to share that we continue to advance our clinical programs across MASH, AUD, and ALD. Beginning with our program in MASH, Last week, we announced the initiation of the global PERFORMA phase 3 trial of pemvidutide in MASH and begin enrolling patients.”
“So, no, we were really happy with EASOL. We had a pretty big presence with our booth, with our team there, met a lot of the KOL. We had receptions as well. And we got the best of EASOL abstract with the oral presentations on our 48-week data.”
“As we shared on our conference call in December, the 48-week data from the impact trials of Pemfidutide and MASH, which evaluated the 1.2 and 1.8 milligram doses, was very encouraging.”
Source not stated
Proxy statement
Start not stated–2020-04-24
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2025-09-16
ALT
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | X4 Pharmaceuticals, Inc (XFOR) | Ph.D M.D. Chief Medical Officer | $179,590 | $1,636,930 |